Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Speciality Medicines IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2021 Industry: Trading Listed Page

Profile
Issue Size 29.14 Cr
Profile
Price Range 117  to  124 per share
Profile
Min Investment ₹124
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Our company is engaged in marketing & distribution of finished formulations of Specialty pharmaceuticals - high-cost oral or injectable medications used to treat complex chronic conditions in Domestic as well as International Market. Having cultivated strong and dependable customer relationships in Specialty pharmaceuticals, we have, through our distributions, established good repo with our customers spreading across more than 20 states of India and more than 35 countries all over the worlds. Our mission is to enhance patient care by supplying high-quality, innovative medicines that address unmet medical needs. With a strong commitment to excellence, we aim to make a positive impact on the lives of patients worldwide. Read More

Basic Info

Face Value 10 per share

Price 117  to  124 per share

P/E (x) 8.8

Sales( Cr.) 58

PAT( Cr.) 9

EPS 14.1

Draft Prospectus

Exchange --

Promoter

Company Promoters

Parth Goyani Sumit Goyani

Pre Issue Share Holding 62.16%

Post Issue Share Holding 43.43%

Listing Details:

Listing Price: 124

Listing Gain: 0%

Current Price: 215

Gain On Issue: 215 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Mar 20, 2026
Closing Date Mar 24, 2026
Allotment Mar 25, 2026
Refund Mar 26, 2026
Delivery of Shares Mar 26, 2026
Listing Date Mar 27, 2026

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 2000 248,000
Retail (Max) -- -- --
S-HNI (Min) 1 2000 248,000
S-HNI (Max) 4 8000 992,000
B-HNI (Min) 5 10000 1,240,000

Objective of the Issue

1. Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje: Manda, Tal. Umargam, Dist. Valsad, Gujarat 2. Product Registration in International Markets and Product Development for sale in international markets.3. Funding for Marketing and Promotional Activities.4. To Meet Working Capital Requirements 5. General Corporate Purpose.

Issue

Category Nos Bid Bid (x)
QIB 21000 2021000 96.2x
NII 1239000 2194000 1.8x
Retail 1090000 922000 0.8x
EMP 0 0 0x
Total 2350000 5137000 2.2x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Speciality Medicines Profit & Loss

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 40 23 28 58
Other Income 0 0 0 0
Total Income 40 23 28 59
Total Expenditure 38 20 22 49
Operating Profit 2 4 5 9
Interest 0 0 1 1
Depreciation 0 0 0 0
Exceptional Income / Expenses 0 0 0 0
Profit Before Tax 2 3 5 9
Provision for Tax 1 1 2 0
Profit After Tax 1 2 3 9
Adjustments 0 0 0 0
Profit After Adjustments 1 2 3 9
Adjusted Earnings Per Share 4.7 4.4 5.7 13.4

Speciality Medicines Balance Sheet

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 2 6 15 30
Minority's Interest 0 0 0 0
Borrowings 0 1 1 3
Other Non-Current Liabilities 0 -0 0 0
Total Current Liabilities 4 6 7 7
Total Liabilities 6 13 23 40
Fixed Assets 2 2 1 2
Other Non-Current Assets 0 0 0 2
Total Current Assets 4 11 21 36
Total Assets 6 13 23 40

Speciality Medicines Cash Flow

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0
Cash Flow from Operating Activities 1 -4 -5 -6
Cash Flow from Investing Activities -2 0 -0 -2
Cash Flow from Financing Activities 2 4 5 8
Net Cash Inflow / Outflow 0 0 -0 1
Closing Cash & Cash Equivalent 0 0 0 1

Speciality Medicines Ratios

# Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 4.7 4.42 5.73 13.38
CEPS(Rs) 5.05 5.19 6.19 13.68
DPS(Rs) 0 0 0 0
Book NAV/Share(Rs) 6.13 15.36 29.44 47.26
Core EBITDA Margin(%) 5.64 15.39 19.16 15.67
EBIT Margin(%) 5.36 14.23 18.79 15.79
Pre Tax Margin(%) 5.29 12.7 16.55 14.91
PAT Margin (%) 3.66 7.27 10.66 14.77
Cash Profit Margin (%) 3.93 8.54 11.5 15.11
ROA(%) 25.61 17.77 16.36 27.5
ROE(%) 76.56 43.3 28.03 37.85
ROCE(%) 69.75 52.41 37.72 34.47
Receivable days 23.38 63.58 107.54 63.57
Inventory Days 4.35 39.87 83.72 79.57
Payable days 12.32 33.46 42.28 14.65
PER(x) 0 0 0 0
Price/Book(x) 0 0 0 0
Dividend Yield(%) 0 0 0 0
EV/Net Sales(x) 0.03 0.31 0.28 0.18
EV/Core EBITDA(x) 0.57 2 1.43 1.13
Net Sales Growth(%) 0 -42.54 18.43 111.71
EBIT Growth(%) 0 52.42 56.44 77.86
PAT Growth(%) 0 14.16 73.7 193.43
EPS Growth(%) 0 -5.86 29.68 133.3
Debt/Equity(x) 0.61 0.62 0.19 0.17
Current Ratio(x) 0.93 1.83 3.12 5.36
Quick Ratio(x) 0.8 1.09 1.92 2.8
Interest Cover(x) 70.21 9.33 8.39 18.03
Total Debt/Mcap(x) 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 107% 13% 0% 0%
Operating Profit CAGR 80% 65% 0% 0%
PAT CAGR 200% 108% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 38% 36% 46% 46%
ROCE Average 34% 42% 49% 49%

Company Contact Information

Speciality Medicines Ltd.

Anita Kumawat

+91 22 4604 5344

investors.grievances@specialitymedicine.com

913, One World West S. No. 396, F P 119 Village- Vejalpur

IPO Lead Manager(s)

Speciality Medicines Ltd.

Unistone Capital Pvt Ltd.

Registrar Info

Speciality Medicines Ltd.

Skyline Financial Services Pvt Ltd

D-153/A, 1st Floor,Okhla Industrial Area, Phase - I, New Delhi - 110020

91-011-26812682/84

91-11-26292681

admin@skylinerta.com

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!